Dr. Paul A Wehrle, M.D. Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 26800 Crown Valley Pkwy., Suite 100, Mission Viejo, CA 92691 Phone: 949-364-6000 Fax: 949-364-1647 |
Catherine Burt Driver, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 26732 Crown Valley Pkwy Ste 151, Mission Viejo, CA 92691 Phone: 949-347-6044 Fax: 949-347-6069 |
Simranjit Kaur Singh, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 26732 Crown Valley Pkwy Ste 151, Mission Viejo, CA 92691 Phone: 949-347-6044 Fax: 949-347-6069 |
Dr. Willilam C Shiel, M.D. Internal Medicine - Rheumatology Medicare: Medicare Enrolled Practice Location: 26800 Crown Valley Pkwy, Suite 330, Mission Viejo, CA 92691 Phone: 949-364-7246 Fax: 949-364-1647 |
Dr. Hernan P Castro-rueda, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 26800 Crown Valley Pkwy, Suite 330, Mission Viejo, CA 92691 Phone: 949-364-7246 Fax: 949-364-1647 |
News Archive
The results of a world-first controlled trial of dialysis start-time in patients with Stage V chronic kidney disease is set to have major impact on the cost and infrastructure of chronic kidney disease (CKD) treatment and dialysis services.
Kansas Attorney General Phill Kline (R), who is running for re-election in November, on Friday said he not was trying to further a political agenda but to protect children when he sought access to the medical records of 90 women and girls who in 2003 underwent late-term abortions at two clinics, the Dodge City Daily Globe reports.
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine and MitoPower LLC were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism.
Researchers have identified clinical features that could help predict which patients with systemic sclerosis are likely to go on to develop pulmonary arterial hypertension (PAH) and therefore benefit most from early treatment.
Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.
› Verified 4 days ago